Aprea Therapeutics Inc. (APRE)
Aprea Therapeutics Statistics
Share Statistics
Aprea Therapeutics has 5.43M shares outstanding. The number of shares has increased by 0.09% in one year.
| Shares Outstanding | 5.43M |
| Shares Change (YoY) | 0.09% |
| Shares Change (QoQ) | 0.06% |
| Owned by Institutions (%) | 0.02% |
| Shares Floating | 4.76M |
| Failed to Deliver (FTD) Shares | 1.59K |
| FTD / Avg. Volume | 5.44% |
Short Selling Information
The latest short interest is 15.18K, so 0.28% of the outstanding shares have been sold short.
| Short Interest | 15.18K |
| Short % of Shares Out | 0.28% |
| Short % of Float | 0.32% |
| Short Ratio (days to cover) | 0.55 |
Valuation Ratios
The PE ratio is -1.4 and the forward PE ratio is -4.09. Aprea Therapeutics's PEG ratio is 0.03.
| PE Ratio | -1.4 |
| Forward PE | -4.09 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0.94 |
| P/FCF Ratio | -1.34 |
| PEG Ratio | 0.03 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Aprea Therapeutics Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.01, with a Debt / Equity ratio of 0.
| Current Ratio | 7.01 |
| Quick Ratio | 7.01 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.67% and return on capital (ROIC) is -74.17%.
| Return on Equity (ROE) | -0.67% |
| Return on Assets (ROA) | -0.54% |
| Return on Capital (ROIC) | -74.17% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-1,851,244.43 |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -66.52% in the last 52 weeks. The beta is 0.82, so Aprea Therapeutics's price volatility has been higher than the market average.
| Beta | 0.82 |
| 52-Week Price Change | -66.52% |
| 50-Day Moving Average | 3.07 |
| 200-Day Moving Average | 3.41 |
| Relative Strength Index (RSI) | 34.96 |
| Average Volume (20 Days) | 29.26K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -14.32M |
| Net Income | -12.96M |
| EBITDA | -14.32M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -2.35 |
Balance Sheet
The company has 22.85M in cash and 0 in debt, giving a net cash position of 22.85M.
| Cash & Cash Equivalents | 22.85M |
| Total Debt | 0 |
| Net Cash | 22.85M |
| Retained Earnings | -321.04M |
| Total Assets | 26.89M |
| Working Capital | 22.85M |
Cash Flow
In the last 12 months, operating cash flow was -13.56M and capital expenditures -15.48K, giving a free cash flow of -13.57M.
| Operating Cash Flow | -13.56M |
| Capital Expenditures | -15.48K |
| Free Cash Flow | -13.57M |
| FCF Per Share | -2.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
APRE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -104.91% |
| FCF Yield | -111.48% |
Analyst Forecast
The average price target for APRE is $15.5, which is 592% higher than the current price. The consensus rating is "Buy".
| Price Target | $15.5 |
| Price Target Difference | 592% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Feb 13, 2023. It was a backward split with a ratio of 1:20.
| Last Split Date | Feb 13, 2023 |
| Split Type | backward |
| Split Ratio | 1:20 |
Scores
| Altman Z-Score | -15.85 |
| Piotroski F-Score | 2 |